Oculis Holding
A quarter of billion-euro licences, a Novo comeback and a flat Nordic index – the State of Nordic BioPharma | 2026:Q3
Analytics
BioArctic’s home-run, a third win for Astra’s Tezspire and a path to phase III for Lytix – the Nordic Pulse | 2026:35
